Loading…
No business profile yet.
Size Electra Therapeutics (ETRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $490M, the 2715th largest of 3,117 United States companies the cockpit tracks. Shares closed at $7.80 on 6 Nov 2026.
Short interest Short interest is 0.7% of the free float (15 Oct 2026).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$61,000 | $0 |
| EBITDA | n/a | -$61.8M | -$26.3M |
| Net income | n/a | -$62.0M | -$24.8M |
| Free cash flow | n/a | -$61.2M | -$26.0M |
| Capital expenditure | n/a | $733,000 | $0 |
| Total debt | n/a | $2.09M | $0 |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ETRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.7% | -10.4% | 7th lowest of 21 |
| Distance from 52-week high | -49.7% | -42.7% | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |